Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cellzome
Heidelberg, Baden-Württemberg, Germanycellzome.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cellzome developed proprietary proteomics technologies enabling the identification and profiling of drug interactions with target proteins in physiologically relevant settings. The company focused on early-stage discovery, particularly kinase inhibitors for inflammatory diseases. No clinical results were published prior to its acquisition by GSK.
- Therapeutic areas
- OncologyImmunologyOther
- Modalities
- small molecules
- Industry
- Biotech
02
Partnerships
GlaxoSmithKline plc – strategic alliances since at least September 2008, culminating in full acquisition in May 2012. Collaborations focused on kinase-targeted therapeutics using Cellzome’s platforms.
Beyond the preview
Go deeper on Cellzome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellzome.